KSTH proposed guidelines on diagnosis and management of thrombosis & coagulopathy in COVID-19 in Kenya

Abstract

Thrombosis and coagulopathy are emerging as the most lethal, yet silent killer complications associated with COVID-19. The evidence  for the complications from clinical, imaging, and laboratory test results is overwhelming. Both clinical experiences in Kenya and publications from afflicted countries indicate that anticoagulation is associated with decreased mortality. Despite the evidence, anticoagulation in COVID-19 patients is neither universally practiced in Kenya nor incorporated in the Country guidelines for the disease management at the moment. The Kenya Society on Thrombosis and Haemostasis (KSTH) has reviewed the evidence from original sources and consensus statements of other professional societies regarding the issue and found there is a strong case for adoption. In response, a guideline for diagnosis and management of thrombosis and coagulopathy is herein recommended for adoption.